Dexcom director receives 5,605-share RSU award

GALA RENEE D reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

GALA RENEE D reported acquisition or exercise transactions in this Form 4 filing.

Dexcom director Renee D. Gala reported an equity grant of company stock. On May 28, 2026, she received 5,605 shares of Dexcom common stock in the form of restricted stock units (RSUs), a stock-based compensation award with no cash purchase price.

After this grant, Gala’s reported direct holdings total 12,486 shares of common stock, including 9,418 unvested RSUs. Of these unvested RSUs, 5,605 were granted on May 28, 2026 and will vest on the earlier of the one-year anniversary of the grant date or Dexcom’s 2027 Annual Meeting of Stockholders. The remaining 3,813 RSUs were granted on March 6, 2025 and are scheduled to vest through March 6, 2028.

Insider Trade Summary

Grant/Award: 5,605 shares

Grant/Award 1 txn

Insider GALA RENEE D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,605	$0.00	$0.00

Holdings After Transaction: Common Stock — 12,486 shares (Direct)

Footnotes (2)

1. F1. The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.
2. F2. Included in this number are 9,418 unvested restricted stock units, 5,605 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 3,813 of which were granted on March 6, 2025 and shall vest through March 6, 2028.

Key Figures

RSUs granted: 5,605 shares Grant price: $0.00 per share Total holdings after grant: 12,486 shares +3 more

6 metrics

RSUs granted 5,605 shares Restricted stock units granted May 28, 2026

Grant price $0.00 per share Reported price for RSU award

Total holdings after grant 12,486 shares Common stock held directly after transaction

Unvested RSUs total 9,418 units Unvested restricted stock units included in holdings

2026 RSU grant vesting 5,605 units Vest on earlier of one-year from May 28, 2026 or 2027 annual meeting

2025 RSU grant 3,813 units Granted March 6, 2025, vesting through March 6, 2028

Key Terms

restricted stock unit (RSU), Annual Meeting of Stockholders, contingent right, unvested restricted stock units

4 terms

restricted stock unit (RSU) financial

"Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share"

A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.

Annual Meeting of Stockholders financial

"will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders"

contingent right financial

"RSU that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement"

unvested restricted stock units financial

"Included in this number are 9,418 unvested restricted stock units, 5,605 of which were granted on May 28, 2026"

FAQ

What insider transaction did Dexcom (DXCM) director Renee D. Gala report?

Renee D. Gala reported receiving a grant of 5,605 restricted stock units (RSUs) of Dexcom common stock on May 28, 2026. This is a stock-based compensation award, not an open-market stock purchase or sale.

How many Dexcom (DXCM) shares does Renee D. Gala hold after this Form 4?

After the reported award, Renee D. Gala holds 12,486 Dexcom common shares directly. This total includes 9,418 unvested restricted stock units that may convert into shares as they vest over time, subject to the stated vesting conditions.

What are the vesting terms of Renee D. Gala’s new Dexcom (DXCM) RSU grant?

The 5,605 RSUs granted on May 28, 2026 will vest 100% on the earlier of the one-year anniversary of the grant date or Dexcom’s 2027 Annual Meeting of Stockholders. Upon vesting and settlement, each RSU delivers one share of common stock.

What other unvested Dexcom (DXCM) RSUs does Renee D. Gala have outstanding?

In addition to the new grant, Gala has 3,813 unvested RSUs from a March 6, 2025 award. These earlier RSUs are scheduled to vest over time through March 6, 2028, adding to her potential future Dexcom share ownership.

Did Renee D. Gala buy or sell Dexcom (DXCM) shares in the market?

The Form 4 shows a grant coded as an acquisition under compensation, not a market trade. The 5,605 shares were received as restricted stock units at a reported price of $0.00 per share, rather than purchased or sold on the open market.

How many of Renee D. Gala’s Dexcom (DXCM) shares are unvested RSUs?

Out of her 12,486 reported Dexcom shares following this transaction, 9,418 are unvested restricted stock units. These include 5,605 RSUs granted on May 28, 2026 and 3,813 RSUs granted on March 6, 2025, each with their own vesting schedules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 05:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GALA RENEE D

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/28/2026		A		5,605(1)	A	$0	12,486(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

2. Included in this number are 9,418 unvested restricted stock units, 5,605 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 3,813 of which were granted on March 6, 2025 and shall vest through March 6, 2028.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Renee D. Gala	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)